All articles by Himaja Ganta
US and UK provide defensive security assistance to Ukraine
The new funding from the US was approved last month.
Russia conducts military drills amid tensions with Ukraine
Approximately 3,000 personnel are participating in the exercises conducted in the regions of Voronezh, Belgorod, Bryansk, and Smolensk.
Biotechnology company Rakuten Medical acquires Medlight
Global biotechnology company Rakuten Medical has announced the acquisition of Swiss medical firm Medlight SA.
US company Aerin Medical announces closing of $48m equity financing
Medical device company Aerin Medical has announced the closing of a $48m equity financing.
J&J’s Biosense received CE Mark for QDOT MICRO ablation catheter
Biosense Webster, a subsidiary of Johnson & Johnson Medical Devices Companies, has received European CE mark approval for the QDOT MICRO radiofrequency (RF) ablation catheter.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
RadNet and Hologic partner on AI tools development for breast health
Imaging services provider RadNet and diagnostic products developer Hologic have agreed to collaborate on developing artificial intelligence (AI) tools for breast health.
BD receives order for 177 million needles and syringes
Medical device maker Becton, Dickinson and Company (BD) has received additional orders from the US and Canada governments for 177 million syringes and needles to support Covid-19 vaccination efforts.
Ortho receives CE mark for second Covid-19 antibody test
In-vitro diagnostics developer Ortho Clinical Diagnostics has received the CE mark for its Vitros Immunodiagnostic Products Anti-SARS-CoV-2 IgG Test, also called the Covid-19 IgG antibody test.
FDA approves CivaTech’s oncology therapy product CivaDerm
The US Food and Drug Administration (FDA) has approved medical technology company CivaTech Oncology’s temporary radiation therapy product CivaDerm.
Senseonics completes patient enrolment in PROMISE clinical trial
Medical technology firm Senseonics has completed patient enrolment in the Eversense PROMISE 180-day sensor clinical study of Eversense continuous glucose monitoring (CGM) system in people with diabetes.